 |
 |
 |
 |
 |
|
 |
 |
 |
 |
Preclinical PK
Absorption Systems performs in vivo animal pharmacokinetic (PK) studies in a variety of species in our AAALAC-accredited animal facility. Most species are available.
Obtaining data from animal PK studies is one of the most important steps in the development of a new chemical entity (NCE). A quantitative measure of drug exposure is necessary in order to interpret preclinical efficacy and toxicity studies. In a typical animal PK study, blood samples are obtained from animals at different time points following a single dose of a test compound. Plasma is prepared and subjected to bioanalysis by LC-MS/MS. In an absolute bioavailability study of an orally administered drug, both oral PK and IV PK must be run. Relative bioavailability studies (oral only with different formulations) can help identify the optimal preclinical formulation for a drug candidate.
We run animal studies for our customers that determine the pharmacokinetics and bioavailability of a test compound after IV, oral, subcutaneous, IP, buccal, or sublingual dosing. We also determine the barriers to bioavailability (e.g., poor absorption or rapid metabolism) using various surgically modified animal models.
We can perform the entire study, in-life portion (dosing and sampling) only or our bioanalytical group can determine the concentrations of your test compound in samples that you collect from a preclinical PK study.
A description of our various in vivo studies can be found in the Study Data Sheets listed in the Related Literature section below. Click on the ones you want to download.
|
Please contact Absorption Systems if you would like our help in determining the pharmacokinetics of your compounds.
Related Literature
This screening assay is used to determine the bioavailability of test compounds relative to a reference compound after oral administration to rats.
Click Here to Download
Determination of brain-to-plasma ratio of a test compound in rats or mice following IV or oral dosing.
Click Here to Download
This assay uses in situ brain perfusion to determine both the potential brain penetration of test compound and whether it is a P-gp substrate.
Click Here to Download
This assay is used to determine the absolute bioavailability of a test compound in mice.
Click Here to Download
This assay is used to determine the bioavailability of a test compound in dogs when the compound is administered by at least two different routes.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male mice.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male rats.
Click Here to Download
This assay is used to determine the bioavailability / exposure of test compounds in male dogs after two routes of administration.
Click Here to Download
This assay uses in vivo carotid infusion to determine the extent of brain penetration of test compound in a physiological setting, including plasma protein binding.
Click Here to Download
This assay is used to determine the bioavailability / exposure of a test compound in dogs after two routes of administration (non-crossover).
Click Here to Download
This screening assay uses the general CYP inhibitor, 1-aminobenzotriazole (ABT), to determine the role of absorption vs. first-pass metabolism in limiting the systemic exposure of a test compound in rats.
Click Here to Download
Brochures
A quick and cost-effective way to distinguish between poor absorption and rapid first-pass metabolism for compounds with poor oral bioavailability
Click Here to Download
Determination of exposure and bioavailability in preclinical species (rodents to primates)
Click Here to Download